Lenvima offers new option in thyroid cancer

Eisai has launched Lenvima (lenvatinib), an oral treatment for progressive, locally advanced or metastatic, differentiated thyroid cancer refractory to radioactive iodine.

Lenvima is available as 4mg and 10mg capsules for once daily administration.
Lenvima is available as 4mg and 10mg capsules for once daily administration.

Lenvatinib is an oral tyrosine kinase inhibitor (RTK) that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3. The drug also inhibits other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor receptors 1-4 and platelet derived growth factor α, KIT and RET.

Further information
View Lenvima drug record 
Summary of Product Characteristics
Manufacturer: Eisai

Clinical studies

The SELECT study (n=392) was a phase III randomised controlled study designed to assess the safety and efficacy of lenvatinib in patients with differentiated thyroid cancer unresponsive to radioactive iodine and with radiographic evidence of progression within the previous 12 months.

Participants were randomised to receive lenvatinib (24mg once daily, n=261) or placebo (n=131) in 28-day cycles.

Median progression-free survival was significantly higher in the lenvatinib group than in the placebo group (18.3 months vs 3.6 months, p<0.0001). The positive effect on progression-free survival was observed across sub-groups of age (above or below 65 years), sex, race, histological subtype, geographic region and those who had received 0 or 1 prior VEGF/VEGF-targeted therapy.

The objective response rate was also significantly higher in the lenvatinib group (64.8%: 4 complete responses, 165 partial responses) than in the placebo group (1.5%: 0 complete responses, 2 partial responses) (p<0.0001).

Adverse reactions occurred more frequently with lenvatinib than with placebo. The most commonly reported adverse effects, occurring in more than 40% of patients in the lenvatinib group, included hypertension, diarrhoea, anorexia, weight loss, fatigue and nausea.




Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases